New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad Genetics’ Prolaris® test to Guide Treatment for Prostate Cancer

NEXT STORY
Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa
PREV STORY
BioXcel Therapeutics to Host Virtual Key Opinion Leader Event to Highlight BXCL501 as a Potential Treatment for Agitation and Opioid Withdrawal Symptoms
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Active Biotech’s rights issue heavily oversubscribed

author_avatar
NASDAQ Market News

Orphazyme reports encouraging arimoclomol clinical trial top-line data in Niemann-Pick disease Type C (NPC)

Orphazyme A/SCompany announcement                                                                                                                   No. 12/2018                                                                                                                                        Company Registration No. 32266355                                                                                                                                                                                              Arimoclomol was well-tolerated in patients ...

author_avatar
NASDAQ Market News

Corbus Pharmaceuticals Completes Enrollment of RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis

author_avatar
NASDAQ Market News